BSE · 524322
Kabra Drugs Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹93 Cr with net profit ₹5 Cr — a 5.32% net margin, versus -169.57% the period before.
Shareholding
As of 2026-09-30
- Public100%
9,727 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
Not enough history.
52-week position
Where the current price sits in its yearly band
The band spans 2.33× from low to high.
Risk flags
Derived from disclosed data
- Reported zero revenue in 3 of the last 8 disclosed periods.
Peer comparison
Trading · ranked #283 of 693 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Adani Enterprises Limited | ₹3,63,802 Cr | 101.43 | 3.71 | 3.66% | 4.59% |
| Avenue Supermarts Limited | ₹2,24,349 Cr | 71.98 | 8.6 | 11.94% | 4.2% |
| Trent Ltd. | ₹1,68,779 Cr | 88.12 | 21.69 | 24.4% | 8.62% |
| FSN E-Commerce Ventures Ltd. | ₹1,04,618 Cr | 314.83 | 63.16 | 19.49% | 2.85% |
| Aditya Infotech Limited | ₹50,886 Cr | 82.37 | 13.87 | 16.16% | 10.38% |
| Vishal Mega Mart Limited | ₹45,148 Cr | 50.19 | 5.7 | 11.37% | 6.45% |
| Aegis Logistics Limited | ₹42,976 Cr | 32.26 | 6.45 | 20.01% | 14.99% |
| Premier Energies Limited | ₹40,670 Cr | 22.98 | 7.88 | 34.23% | 19.11% |
| Redington Limited | ₹27,339 Cr | 13.62 | 2.54 | 18.62% | 1.31% |
| Honasa Consumer Limited | ₹16,378 Cr | 57.17 | 11.02 | 19.03% | 10.3% |
| Kabra Drugs Ltd.(this company) | ₹49 Cr | 6.31 | 1.45 | 22.8% | 5.33% |
AI analysis
AI-generated · google/gemini-2.5-flashKabra Drugs Ltd. has a market capitalization of Rs 51 Cr. The company's PE ratio stands at 10.38, with an EPS of 2.09. Its book value is Rs 12.49, and it has a debt-to-equity ratio of 0.08.
Positives
- +The company has a low debt-to-equity ratio of 0.08.
- +Return on Capital Employed (ROCE) is 19.05%.
Negatives
- −Revenue in Mar 2024 was Rs 0 Cr, indicating no operational revenue for the period.
- −Promoter holding is 0% as of June 30, 2026.
- −Annual net profit was negative for five consecutive periods from Mar 2021 to Mar 2025, with a net profit of -1.0856 Cr in Mar 2025.
- −Profit margin is 5.36%, based on revenue of Rs 0.64 Cr.
Financial performance
The company reported revenue of Rs 0.64 Cr. Profitability for the most recent annual period was 5.36%. For the year ending March 2025, revenue was Rs 0.64 Cr, with a net profit of -1.0856 Cr. In the latest available quarterly results (Mar 2026), revenue was Rs 35.41 Cr and net profit was Rs 1.06 Cr.
Profitability & Returns
Kabra Drugs Ltd. recorded a Return on Equity (ROE) of 16.75% and a Return on Capital Employed (ROCE) of 19.05%. The overall profit margin for the company is 5.36%.
Balance Sheet
The company maintains a low debt-to-equity ratio of 0.08, indicating a low reliance on debt for financing its operations. No details on other specific assets or liabilities are provided.
Ownership & Pledges
As of June 30, 2026, public shareholding in Kabra Drugs Ltd. was 100%. Promoter holding is 0%, with no DII or FII participation. There are no reported promoter pledges. The total number of shareholders was 9680.
Data as of — price: 2026-11-14 · financials: Mar 26 · shareholding: Sep 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.